Atrial-selective sodium channel blockers: Do they exist?

Journal of Cardiovascular Pharmacology

Volumn 52, Issue 2, 2008, Pages 121-128

  Burashnikov, Alexander ^a   Antzelevitch, Charles ^a  

^a MASONIC MEDICAL RESEARCH LABORATORY   (United States)

Author keywords

Atrial fibrillation; Cardiac arrhythmias; Pharmacology

Indexed keywords

2 [7 [3 (4 CYANOPHENOXY) 2 HYDROXYPROPYL] 9 OXA 3,7 DIAZABICYCLO[3.3.1]NON 3 YL]ETHYLCARBAMIC ACID TERT BUTYL ESTER; AMIODARONE; ANTIARRHYTHMIC AGENT; DISOPYRAMIDE; FLECAINIDE; LIDOCAINE; MEXILETINE; MORACIZINE; PRAJMALINE; PROCAINAMIDE; PROPAFENONE; QUINIDINE; RANOLAZINE; SODIUM CHANNEL; SODIUM CHANNEL BLOCKING AGENT; TEDISAMIL;

ACTION POTENTIAL; ACUTE CORONARY SYNDROME; ANTIARRHYTHMIC ACTIVITY; CARDIOSELECTIVITY; DRUG BINDING; DRUG EFFICACY; HEART ATRIUM; HEART ATRIUM FIBRILLATION; HEART MUSCLE REFRACTORY PERIOD; HEART VENTRICLE; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; SUPRAVENTRICULAR TACHYCARDIA; UNSPECIFIED SIDE EFFECT; ANIMAL; DRUG EFFECT; HEART MUSCLE; METABOLISM; PATHOPHYSIOLOGY;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; HEART ATRIA; MYOCARDIUM; SODIUM CHANNEL BLOCKERS;

EID: 50949115380     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31817618eb     Document Type: Review

References (47)

1. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation - Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol. 2006;48:854-906.
2. Nattel S, Carlsson L. Innovative approaches to anti-arrhythmic drug therapy. Nat Rev Drug Discov. 2006; 5:1034-1049.
3. Blaauw Y, Gogelein H, Tieleman RG, et al. "Early" class III drugs for the treatment of atrial fibrillation: Efficacy and atrial selectivity of AVE0118 in remodeled atria of the goat. Circulation. 2004;110:1717-1724.
4. Goldstein RN, Khrestian C, Carlsson L, et al. Azd7009: A new anti-arrhythmic drug with predominant effects on the atria effectively terminates and prevents reinduction of atrial fibrillation and flutter in the sterile pericarditis model. J Cardiovasc Electrophysiol. 2004;15: 1444-1450.
5. Fedida D, Orth PM, Chen JY, et al. The mechanism of atrial anti-arrhythmic action of RSD1235. J Cardiovasc Electrophysiol. 2005;16: 1227-1238.
6. CAST Investigators. Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med. 1989;321:406-412.
7. Burashnikov A, Di Diego JM, Zygmunt AC, et al. Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: Differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. Circulation, 2007;116:1449-1457.
8. Burashnikov A, Belardinelli L, Antzelevitch C. Ranolazine and propafenone both suppress atrial fibrillation but ranolazine unlike propafenone does it without prominent effects on ventricular myocardium. Heart Rhythm. 2007;4:S163.
9. Burashnikov A, Di Diego JM, Zygmunt AC, et al. Atrial-selective sodium channel block as a strategy for suppression of atrial fibrillation. Ann N Y Acad Sci. 2008;1123:105-112.
10. Vaughan Williams EM. A classification of antiarrhythmic actions reassessed after a decade of new drugs. J Clin Pharmacol. 1984;24: 129-147.
11. Whalley DW, Wendt DJ, Grant AO. Basic concepts in cellular cardiac electrophysiology: Part II: Block of ion channels by antiarrhythmic drugs. PA C E . 1995;18:1686-1704.
12. Carmeliet E, Mubagwa K. Antiarrhythmic drugs and cardiac ion channels: Mechanisms of action. Prog Biophys Mol Biol. 1998;70:1-72.
13. Hondeghem LM, Katzung BG. Mechanism of action of antiarrhythmic drugs. In: Sperelakis N, ed. Physiology and pathophysiology of the heart. 3rd ed. Norwell, MA: Kluwer Academic Publishers; 1995:589-603.
14. Kneller J, Kalifa J, Zou R, et al. Mechanisms of atrial fibrillation termination by pure sodium channel blockade in an ionically-realistic mathematical model. Circ Res. 2005;96:e35-e47.
15. Kumagai K, Nakashima H, Tojo H, et al. Pilsicainide for atrial fibrillation. Drugs. 2006;66:2067-2073.
16. Nattel S. New ideas about atrial fibrillation 50 years on. Nature. 2002;415: 219-226.
17. Wijffels MC, Dorland R, Mast F, et al. Widening of the excitable gap during pharmacological cardioversion of atrial fibrillation in the goat: Effects of cibenzoline, hydroquinidine, flecainide, and d-sotalol. Circulation. 2000;102:260-267.
18. Antzelevitch C, Belardinelli L, Zygmunt AC, et al. Electrophysiologic effects of ranolazine: A novel anti-anginal agent with antiarrhythmic properties. Circulation. 2004;110:904-910.
19. Undrovinas AI, Belardinelli L, Undrovinas NA, et al. Ranolazine improves abnormal repolarization and contraction in left ventricular myocytes of dogs with heart failure by inhibiting late sodium current. J Cardiovasc Electrophysiol. 2006;17:S161-S177.
20. Spinelli W, Parsons RW, Colatsky TJ. Effects of WAY-123,398, a new Class-III antiarrhythmic agent, on cardiac refractoriness and ventricular fibrillation threshold in anesthetized dogs - A comparison with UK-68798, e-4031, and DL- Sotalol. J Cardiovasc Pharmacol. 1992;20:913- 922.
21. Antzelevitch C, Shimizu W, Yan GX, et al. The M cell: Its contribution to the ECG and to normal and abnormal electrical function of the heart. J Cardiovasc Electrophysiol. 1999;10:1124-1152.
22. Burashnikov A, Antzelevitch C. Late-Phase 3 EAD. A unique mechanism contributing to initiation of atrial fibrillation. PACE . 2006;29:290-295.
23. Gintant GA. Characterization and functional consequences of delayed rectifier current transient in ventricular repolarization. Am J Physiol. 2000; 278:H806-H817.
24. Langenfeld H, Weirich J, Kohler C, et al. Comparative analysis of the action of class I antiarrhythmic drugs (lidocaine, quinidine, and prajmaline) in rabbit atrial and ventricular myocardium. J Cardiovasc Pharmacol. 1990;15:338-345.
25. Hiroe K, Hisatome I, Tanaka Y, et al. Tonic block of the Na+ current in single atrial and ventricular guinea-pig myocytes, by a new antiarrhythmic drug, Ro 22-9194. Fundam Clin Pharmacol. 1997;11:402-407.
26. Furukawa T, Koumi S, Sakakibara Y, et al. An analysis of lidocaine block of sodium current in isolated human atrial and ventricular myocytes. J Mol Cell Cardiol. 1995;27:831-846.
27. Ahmmed GU, Hisatome I, Kurata Y, et al. Analysis of moricizine block of sodium current in isolated guinea-pig atrial myocytes. Atrioventric-ular difference of moricizine block. Vascul Pharmacol. 2002;38: 131-141.
28. Lemmens-Gruber R, Marei H, Heistracher P. Electrophysiological properties of the propafenone-analogue GE 68 (1-[3-(phenylethyl)-2-benzofuryl]-2- (propylamino)-ethanol) in isolated preparations and ventricular myocytes of guinea-pig hearts. Naunyn Schmiedebergs Arch Pharmacol. 1997;355:230-238.
29. Nemeth M, Virag L, Hala O, et al. The cellular electrophysiological effects of tedisamil in human atrial and ventricular fibers. Cardiovasc Res. 1996; 31:246-248.
30. max) of action potential in guinea-pig cardiac muscles. J Mol Cell Cardiol. 1987;19:367-377.
31. Carlsson L, Chartier D, Nattel S. Characterization of the in vivo and in vitro electrophysiological effects of the novel antiarrhythmic agent AZD7009 in atrial and ventricular tissue of the dog. J Cardiovasc Pharmacol. 2006;47:123-132.
32. Burashnikov A, Mannava S, Antzelevitch C. Transmembrane action potential heterogeneity in the canine isolated arterially-perfused atrium: effect of IKr and Ito/IKur block. Am J Physiol. 2004;286:H2393-H2400.
33. Golod DA, Kumar R, Joyner RW. Determinants of action potential initiation in isolated rabbit atrial and ventricular myocytes. Am J Physiol. 1998;274:H1902-H1913.
34. Li GR, Lau CP, Shrier A. Heterogeneity of sodium current in atrial vs epicardial ventricular myocytes of adult guinea pig hearts. J Mol Cell Cardiol. 2002;34:1185-1194.
35. Fahmi AI, Patel M, Stevens EB, et al. The sodium channel beta-subunit SCN3b modulates the kinetics of SCN5a and is expressed heteroge-neously in sheep heart. J Physiol. 2001;537:693-700.
36. Ko SH, Lenkowski PW, Lee HC, et al. Modulation of Na(v)1.5 by beta1-and beta3-subunit co-expression in mammalian cells. Pflugers Arch. 2005;449:403-412.
37. Gaborit N, Le BS, Szuts V, et al. Regional and tissue specific transcript signatures of ion channel genes in the non-diseased human heart. J Physiol. 2007;582:675-693.
38. Hu D, Zygmunt AC, Burashnikov A, et al. Sodium channel of canine atrial and ventricular cells differ with respect to voltage dependence of inactivation. Heart Rhythm. 2007;4:S148.
39. Scirica BM, Morrow DA, Hod H, et al. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: Results from the Metabolic Efficiency with Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation. 2007;116:1647-1652.
40. Antzelevitch C. Ranolazine: a new antiarrhythmic agent for patients with non-ST-segment elevation acute coronary syndromes? Nat Clin Pract Cardiovasc Med. 2008;5:248-249.
41. Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death - Executive Summary. J Am Coll Cardiol. 2006;48:1064-1108.
42. Crijns HJ, Van GI, Walfridsson H, et al. Safe and effective conversion of persistent atrial fibrillation to sinus rhythm by intravenous AZD7009. Heart Rhythm. 2006;3:1321-1331.
43. Ehrlich JR, Cha TJ, Zhang L, et al. Cellular electrophysiology of canine pulmonary vein cardiomyocytes: action potential and ionic current properties. J Physiol. 2003;551:801-813.
44. Gaspo R, Bosch RF, Bou-Abboud E, et al. Tachycardia-induced changes in Na+ current in a chronic dog model of atrial fibrillation. Circ Res. 1997; 81:1045-1052.
45. Wijffels MC, Kirchhof CJ, Dorland R, et al. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation. 1995;92:1954-1968.
46. Bosch RF, Zeng X, Grammer JB, et al. Ionic mechanisms of electrical remodeling in human atrial fibrillation. Cardiovasc Res. 1999;44: 121-131.
47. Eijsbouts S, Ausma J, Blaauw Y, et al. Serial cardioversion by Class IC drugs during 4 months of persistent atrial fibrillation in the goat. J Cardiovasc Electrophysiol. 2006;17:648-654.